




**Claim Amendments**





Please cancel claims 1-79 without prejudice and please add new claims 80-113 as follows. This listing of claims will replace all prior versions and listings of claims in the instant application.

**Listing of Claims:**

1-79. (Cancelled)


80. (New) A laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof, selected from the group consisting of:






wherein R is a core cyclic peptide of laspartomycin, and  
n is an integer from 8 to 10.


81. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:




82. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:




83. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:




84. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:




85. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:








86. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:












87. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 80 according to structure:




88. (New) A laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof, selected from the group consisting of:











wherein R is a core cyclic peptide of laspartomycin, and  
n is an integer from 8 to 10.


89. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:



90. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




91. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:







92. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




93. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




94. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




95. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




96. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




97. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




98. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




99. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




100. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




101. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:



102. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




103. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 according to structure:




104. (New) The laspartomycin derivative or a pharmaceutically acceptable salt or hydrate thereof of claim 88 wherein said laspartomycin derivatives have polyamide linkers in L stereochemistry at the  $\alpha$  carbon of one or more amino acid substituents.

105. (New) The laspartomycin derivative according to claim 80, 88 or 104 wherein R has the structure:




106. (New) A pharmaceutical composition comprising one or more laspartomycin derivatives according to claim 80, 88 or 104 and a pharmaceutically acceptable excipient, carrier or diluent.

107. (New) The pharmaceutical composition according to claim 106 wherein R has the structure:



108. (New) A method for treating or preventing a microbial infection, comprising administering to a subject in need thereof one or more laspartomycin derivatives according to claim 80, 88 or 104 in an amount effective to treat or prevent a microbial infection.

109. (New) The method according to claim 108 wherein R has the structure:



110. (New) A method for treating or preventing a microbial infection, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 106 in an amount effective to treat or prevent a microbial infection.

111. (New) The method according to claim 110 wherein the microbial infection is due to bacteria or fungi.

112. (New) The method according to claim 110 wherein the microbial infection is due to Gram positive bacteria.

113. (New) The method according to claim 110 wherein R has the structure:

